Patents Assigned to ADURO BIOTECH HOLDINGS, EUROPE B.V.
-
Patent number: 11959924Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: GrantFiled: June 28, 2021Date of Patent: April 16, 2024Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20220135671Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: November 30, 2020Publication date: May 5, 2022Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
-
Publication number: 20210379183Abstract: Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.Type: ApplicationFiled: May 28, 2021Publication date: December 9, 2021Applicants: CHINOOK THERAPEUTICS, INC., ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Teun VAN DE LAAR, Somayeh HONARMAND, John DULOS, Eduard DE COCK
-
Publication number: 20210325404Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: ApplicationFiled: June 28, 2021Publication date: October 21, 2021Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20210221900Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 11047864Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: GrantFiled: September 11, 2018Date of Patent: June 29, 2021Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Patent number: 10961316Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: GrantFiled: August 12, 2019Date of Patent: March 30, 2021Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 10851164Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: April 13, 2018Date of Patent: December 1, 2020Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
-
Patent number: 10808030Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.Type: GrantFiled: October 2, 2017Date of Patent: October 20, 2020Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
-
Publication number: 20200079859Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: ApplicationFiled: August 12, 2019Publication date: March 12, 2020Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 10494436Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.Type: GrantFiled: July 28, 2017Date of Patent: December 3, 2019Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
-
Patent number: 10377830Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: GrantFiled: May 14, 2018Date of Patent: August 13, 2019Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Publication number: 20190170766Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: ApplicationFiled: September 11, 2018Publication date: June 6, 2019Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20180312587Abstract: The present invention relates to anti-SIRP antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: April 13, 2018Publication date: November 1, 2018Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
-
Patent number: 10107821Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: GrantFiled: September 5, 2014Date of Patent: October 23, 2018Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20180258176Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: ApplicationFiled: May 14, 2018Publication date: September 13, 2018Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 9969808Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: GrantFiled: January 8, 2016Date of Patent: May 15, 2018Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Publication number: 20180037654Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.Type: ApplicationFiled: October 2, 2017Publication date: February 8, 2018Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Joost KREIJTZ, David Lutje HULSIK, Paul VINK
-
Publication number: 20180030137Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.Type: ApplicationFiled: July 28, 2017Publication date: February 1, 2018Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Joost KREIJTZ, David Lutje HULSIK, Carlos Ricardo RODRIGUES DOS REIS
-
Patent number: 9527916Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.Type: GrantFiled: December 19, 2012Date of Patent: December 27, 2016Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink